Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Jefferies Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)

Tipranks - Tipranks - Fri Apr 3, 9:06AM CDT

Jefferies analyst Michael Leuchten maintained a Buy rating on GlaxoSmithKline today and set a price target of £24.50.

End of Quarter Sale - 50% Off TipRanks

According to TipRanks, Leuchten is an analyst with an average return of -4.7% and a 50.44% success rate.

In addition to Jefferies, GlaxoSmithKline also received a Buy from TipRanks – xAI’s xAi Health Care GB in a report issued on March 24. However, on March 31, Barclays maintained a Sell rating on GlaxoSmithKline (LSE: GSK).

See the top stocks recommended by analysts >>

Based on GlaxoSmithKline’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p8.62 billion and a net profit of p636 million. In comparison, last year the company earned a revenue of p8.12 billion and had a net profit of p414 million

Based on the recent corporate insider activity of 324 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GSK in relation to earlier this year.

Read More on GB:GSK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).